Actively Recruiting
Study of IAP0971 Safety and Effectiveness in Adults with Advanced Tumors Including Non-Small Cell Lung Cancer
Led by SUNHO(China)BioPharmaceutical CO., Ltd. · Updated on 2025-01-15
78
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerance, and effectiveness of IAP0971 for treating advanced malignant tumors, including advanced or metastatic non-small cell lung cancer NSCLC. The study involves two phases Phase I focuses on dose escalation to determine the maximum tolerated dose MTD and safety profile, while Phase II assesses the therapys effects on patients with specific tumor characteristics, such as PD-L1 positivity and negative driver genes. This research aims to find a recommended dose and understand how well the treatment works in these advanced cancer patients. The study includes a Phase I dose-escalation phase where 14 to 48 participants with advanced malignancies receive increasing doses of IAP0971, starting at 0.0005 mgkg up to a maximum of 18.0 mgkg, administered once every three weeks in 3-week cycles. Following this, Phase II involves 20 to 30 patients with advanced or metastatic NSCLC who have not received prior systemic antitumor therapy, receiving IAP0971 at the recommended dose determined in Phase I. This phase uses an open-label, non-randomized, single-arm design to explore treatment effects with infusions every three weeks. Participants will be closely monitored throughout the study with assessments including adverse event tracking, vital signs, laboratory tests, and tumor evaluations using RECIST 1.1 criteria. Tumor assessments occur every two cycles approximately every six weeks during the first 48 weeks, then every four cycles thereafter until disease progression or other study endpoints like withdrawal or death. Safety and effectiveness outcomes such as progression-free survival and dose-limiting toxicities will be evaluated, with follow-up continuing up to two years or until disease progression.
CONDITIONS
Brief Title
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Research Team
Y
YuanKai Shi, doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here